---
title: "adjuvant therapy of rcc"
slug: "adjuvant-therapy-of-rcc"
date: "2024-01-03"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[Treatment principles-of-renal-cell-carcinoma]]

# adjuvant therapy of rcc

- Few data support adjuvant therapy.
- Although S-TRAC trial suggested â†‘ 1.2 y in DFS w/ sunitinib, ASSURE & PROTECT trials w/ no benefit in DFS for sunitinib, sorafenib, or pazopanib, & ATLAS trial w/ no benefit in DFS for axitinib (NEJM 2016;375:2246; Lancet 2016;387:2008; JCO 2017;35:3916; Ann Oncol 2018;29(12):2371).
- Early data w/ adjuvant immunotherapy.
- Adjuvant pembrolizumab improves DFS (NEJM 2021;385:683)
  - [[adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma.md|Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma]]
